Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

@article{Farag2005OutcomeOI,
  title={Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.},
  author={Sherif S. Farag and Amy S. Ruppert and Krzysztof Mr{\'o}zek and Robert J. Mayer and Richard M Stone and Andrew J. Carroll and Bayard L. Powell and Joseph O. Moore and Mark J. Pettenati and Prasad R. K. Koduru and Judith Stamberg and Maria R. Baer and Annemarie W Block and James W. Vardiman and Jonathan E Kolitz and Charles A Schiffer and Richard A Larson and Clara D. Bloomfield},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 3},
  pages={482-93}
}
PURPOSE Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML). PATIENTS AND METHODS In 490 patients, induction included cytarabine and daunorubicin (AD) or cytarabine and escalated doses of daunorubicin and etoposide +/- PSC-833 (ADE/ADEP). Intensification included one cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I), three HDAC cycles… CONTINUE READING